ENTRADA THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ENTRADA THERAPEUTICS, INC. (TRDA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $11.16 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $11.93, a 0.08% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $11.94, a 13.04% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $13.73, a 12.17% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $12.24, a 4.88% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $10.97, a 22.58% decline from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $14.17, a 2.31% increase from fiscal 2023.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $13.85.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.16 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $11.93 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $10.97 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $11.02 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $11.28 10-Q · filed 2025-08-06 | |||
| 2025-03-31 | $11.94 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $14.17 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $14.12 10-Q · filed 2024-11-05 | |||
| 2024-06-30 | $14.06 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $13.73 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $13.85 10-K · filed 2024-03-13 | |||
| 2023-09-30 | $13.79 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $12.81 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $12.24 10-Q · filed 2023-05-10 | |||
| 2022-09-30 | $11.34 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $11.04 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $11.67 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |